Upon joining the study, the patient will be informed about the trial’s purpose, which is to evaluate the safety and tolerability of a treatment called stereotactic interstitial photodynamic therapy (iPDT) using a substance known as PD L 506.

The patient will be required to provide written informed consent, confirming their understanding and agreement to participate in the study.

The patient will undergo an initial assessment to confirm eligibility. This includes verifying the diagnosis of glioblastoma and ensuring the tumor meets specific criteria, such as size and location.

Additional assessments will include checking the patient’s overall health status, including blood tests to ensure adequate blood cell counts and liver function.

The patient will be prepared for the treatment phase, which involves the administration of aminolevulinic acid hydrochloride in the form of an oral solution called Gliolan 30 mg/ml.

The medication is taken orally to help highlight the tumor during the photodynamic therapy.

The patient will undergo the stereotactic interstitial photodynamic therapy (iPDT). This involves using light to activate the medication within the tumor, aiming to destroy cancer cells.

The procedure is performed under medical supervision to ensure safety and effectiveness.

Following the therapy, the patient will be monitored for any side effects or adverse reactions. This monitoring period lasts for two weeks.

The focus will be on identifying any treatment-emergent adverse events, particularly those of higher severity.

The patient will have regular follow-up assessments to evaluate the treatment’s impact on the tumor and overall health.

These assessments will include imaging tests and clinical evaluations to track progress and detect any changes.